Dosage & AdministrationDrug labelPrior authorizationFinancial assistance
Patient education

Sotyktu

(deucravacitinib)
deucravacitinib 6 MG Oral Tablet [Sotyktu]
NO BLACK BOX WARNING

Dosage & administration

drug label

Sotyktu prescribing information

Have more Sotyktu questions?

Submit MSL Request
Learn More

Need to report a Sotyktu issue?

ONLINE FORMReport adverse event
Learn More

prior authorization

Sotyktu Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request
Coverage Authorization Appeals
Formulary Exception Letter
Coverage Redetermination Letter
Learn More

Benefits investigation

Sotkyu 360 Start Form
Patient Authorization - Esign Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Sotyktu Financial assistance options

Co-pay savings program

commercial only
Sotkyu 360 Start Form
Enroll in Patient Savings Program
Patient Authorization - Esign Form
Learn More

Bridge program

commercial only
Sotkyu 360 Start Form
Bridge Program
Patient Authorization - Esign Form
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Learn More

patient education

Sotyktu Patient education

Getting started on Sotyktu

NOT PROVIDED BY BRANDInstructions For Use: Plaque Psoriasis

Patient toolkit

About Sotyktu
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Sotyktu
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Sotyktu Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
My Experience Tracker
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Sotyktu FAQs

Is SOTYKTU safe to use during pregnancy?Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, no effects on embryo-fetal development were observed with oral administration of deucravacitinib to rats and rabbits during organogenesis at doses that were at least 91 times the maximum recommended human dose (MRHD) of 6 mg once daily. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.
Can SOTYKTU be used during lactation?There are no data on the presence of deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Deucravacitinib is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.
Is SOTYKTU safe for use in pediatric patients?The safety and effectiveness of SOTYKTU in pediatric patients have not been established.
Is SOTYKTU safe for use in elderly patients?No overall differences in effectiveness of SOTYKTU have been observed between patients 65 years of age and older and younger adult patients. However, during the Week 0-16 period, for those subjects who received SOTYKTU without switching treatment arms, there was a higher rate of overall serious adverse reactions, including serious infections, and discontinuations due to adverse reactions compared with younger adults.
Is dosage adjustment necessary for patients with renal impairment?No dose adjustment of SOTYKTU is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.
Is dosage adjustment necessary for patients with hepatic impairment?No dose adjustment of SOTYKTU is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. SOTYKTU is not recommended for use in patients with severe hepatic impairment.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.